This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Novo Nordisk A/S
Drug Names(s): Glucagon for injection; Glucagon G Novo
Description: GlucaGen is purified recombinant human glucagon, a 29 amino acid peptide hormone liberated in the cells of the islets of Langerhans in the pancreas. Glucagon is generally viewed as a hormone that opposes the action of insulin in peripheral tissues, predominantly the liver. It regulates glucose homeostasis through enhanced synthesis and mobilization of glucose in the liver.
Novo Nordisk and Eisai
In April 1999, Novo Nordisk and Eisai entered a Distribution and Promotion Agreement in which Eisai will exclusively distribute and promote in Japan Glucagon G Novo. Under this agreement Eisai will start distribution from June 1, 1999.
In August 1999, Novo Nordisk and Ben Venue announced that GlucaGen will be marketed in the United States by Bedford Laboratories, a division of Ben Venue Laboratories, Inc., a member of the Boehringer Ingelheim family of companies. The multi-year agreement takes effect immediately. Under terms of the contract, Bedford Laboratories will be responsible for promoting, marketing, distributing and selling GlucaGen in the US, including Puerto Rico and the United States Virgin Islands.
In collaboration with Novo Nordisk, ZymoGenetics developed a process for the production of this protein that is currently used by Novo Nordisk in the manufacture of GlucaGen. ZymoGenetics derives royalties on this...See full deal structure in Biomedtracker
Partners: EA Pharma Co., Ltd. Boehringer Ingelheim GmbH Bristol-Myers Squibb Company
Pink Sheet Novo Nordisk GlucaGen
Additional information available to subscribers only: